Please Subscribe to get a daily link to Pat's blog via email


Your privacy is important to us. We will never spam you and keep your personal data secure.


4 04, 2012

More about perifosine’s uncertain future

Tags: , , |1 Comment

Monday I shared the disappointing news about how the promising anti-myeloma drug, perifosine, might not ever make it to market. Here are excerpts from a more measured, detailed look at what may happen now that perifosine failed to extend the lives of patients with advanced colon cancer from an online newsletter used by serious investors,

20 07, 2010

Even The Associated Press Makes Mistakes!

Tags: , , |0 Comments

Thursday I quoted the Associated Press (AP) in a story I did about a new anti-myeloma drug, perifosine.  You would have had to read it very carefully, but AP is admiting it made a mistake which is good news for multiple myeloma patients.  NEW YORK   Correction: Keryx's perifosine drug storyIn a story July 14 about Keryx Biopharmaceuticals, The Associated

15 07, 2010

Perifosine Continues To Show Strong Anti-Cancer Results: Multiple Myeloma Perifosine Update

Tags: , , , |0 Comments

Keryx's perifosine gets second orphan drug status(AP) – 10 hours agoNEW YORK — Keryx Biopharmaceuticals Inc. said Wednesday that its experimental cancer drug perifosine received orphan drug status as a treatment for neuroblastoma, a cancer that affects the nervous system and mostly strikes young children...Perifosine also has orphan drug status as a colorectal cancer treatment,

9 07, 2010

Anti-Myeloma Drug, Perifosine, May Also Work Against Colon Cancer

Tags: , , , , , |0 Comments

Interesting news I wanted to share about one of several new anti-myeloma therapy agents, perifosine.  Currently in Phase 3 trials in combination with Velcade, perifosine apparently has anti-cancer properties which go far beyond multiple myeloma:  Aeterna Zentaris Receives Positive Scientific Advice from the European Medicines Agency for its Phase 3 Trial with Perifosine in Colorectal CancerThe

21 12, 2009

Details About New Anti-Myeloma Drug, Perifosine

Tags: , , , , |0 Comments

Here is a clinical summary about the new myeloma drug I wrote about last night, perifosine, from a Website named ""KRX-0401 (perifosine) is a potential oral anti-cancer agent that suppresses the pathways associated with the programmed growth, death, differentiation and survival of cells. Developed by Keryx, the drug is most effective in modulating Akt, as

21 12, 2009

Keryx Biopharmaceuticals, Inc. Initiates Phase 3 Registration Trial of KRX-0401 (Perifosine) for Treatment of Patients with Advanced Multiple Myeloma

Tags: , , , , |0 Comments

Here is info about a newly organized Phase 3 study combining perifosine with Velcade:NEW YORK, Dec 16, 2009 /PRNewswire-FirstCall via COMTEX/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today the initiation of a Phase 3 registration clinical trial for KRX-0401 (perifosine), the Company's PI3K/Akt pathway inhibitor, in relapsed / refractory multiple myeloma patients. The trial,